Stay updated on Clinical Trial: KZR-616 in Active Polymyositis or Dermatomyositis

Sign up to get notified when there's something new on the Clinical Trial: KZR-616 in Active Polymyositis or Dermatomyositis page.
Latest website image capture
Clouds background image

Latest updates to the Clinical Trial: KZR-616 in Active Polymyositis or Dermatomyositis page

  1. Check
    today
    Change Detected
    Difference
    0.5%
    Check dated 2024-10-17T19:55:14.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.
    Difference
    0.3%
    Check dated 2024-10-03T05:07:44.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    New detailed secondary outcome measures for the treatment of patients with dermatomyositis using zetomipzomib (KZR-616) have been added, including various assessments of disease activity and pharmacokinetic parameters.
    Difference
    46%
    Check dated 2024-09-25T22:46:27.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    ClinicalTrials.gov is addressing delays in displaying study record information, and the website has been updated to version 2.10.5, replacing the previous version 2.10.3.
    Difference
    1%
    Check dated 2024-09-18T16:46:45.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    The website has been updated from version 2.10.2 to 2.10.3.
    Difference
    0.1%
    Check dated 2024-09-04T05:03:48.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-08-21T00:46:39.000Z thumbnail image

Stay in the know with updates to Clinical Trial: KZR-616 in Active Polymyositis or Dermatomyositis

Enter your email address, and we'll notify you when there's something new on the Clinical Trial: KZR-616 in Active Polymyositis or Dermatomyositis page.